Dr. Robert Aboussaly, MD, explains up-to-date approaches to treating upper tract urothelial carcinoma, including risk-stratification in diagnosis, nephroureterectomy, neoadjuvant chemotherapy, post-operative intravesical chemotherapy, and more.
Read More
Dr. Ryan P. Terlecki, MD, FACS, explains why and how clinicians should not simply carry out therapies to prevent or arrest disease quickly. They should also aim to minimize possible late side effects, social hazards, and cost for their patients.
Read More
Dr. Alan H. Bryce, MD, argues that there is not yet enough substantive data and research to justify the FDA approving using adjuvant Sunitinib to treat high risk renal cell carcinoma.
Read More
Erik P. Castle, MD, discusses the most recent advances in renal cell carcinoma treatment, especially in regards to individualized medicine, immunotherapy, robotics, partial nephrectomy, and other surgeries.
Read More
Dr. Alan H. Bryce, MD, discusses synthetic lethality regarding BRCA deficient tumors, the role of PARP inhibitors and resistance to them, and the importance of germline testing when treating cancer patients.
Read More